selumetinib
Selected indexed studies
- Selumetinib in Children with Inoperable Plexiform Neurofibromas. (N Engl J Med, 2020) [PMID:32187457]
- Selumetinib. (, 2006) [PMID:40127361]
- Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. (Lancet, 2025) [PMID:40473450]
_Worker-drafted node — pending editorial review._
Connections
selumetinib is a side effect of
Sources
- Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma. (2024) pubmed
- Selumetinib in Children with Inoperable Plexiform Neurofibromas. (2020) pubmed
- Selumetinib. (2006) pubmed
- Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. (2025) pubmed
- Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. (2023) pubmed
- Selumetinib. (2012) pubmed
- Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. (2016) pubmed
- Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. (2019) pubmed
- Selumetinib: a selective MEK1 inhibitor for solid tumor treatment. (2023) pubmed
- Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. (2022) pubmed